DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 16, 2022 at 03:11 am EDT
Share
DongKook Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 5,825.44 million compared to KRW 2,685.9 million a year ago. Net income was KRW 15,699.23 million compared to KRW 15,125.28 million a year ago. Basic earnings per share from continuing operations was KRW 357 compared to KRW 344 a year ago. Diluted earnings per share from continuing operations was KRW 351 compared to KRW 338 a year ago. Basic earnings per share was KRW 357 compared to KRW 344 a year ago. Diluted earnings per share was KRW 351 compared to KRW 338 a year ago.
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.
DONGKOOK PHARMACEUTICAL CO., LTD. 
